#Adaura
LightNews LightNews
cancerletter.com
Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research
https://cancerletter.com/funding-opportunities/20260925_8a/
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds - The Cancer Letter
Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared
cancerletter.com
September 28, 2026 at 10:00 PM
cancerletter.com
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds
https://cancerletter.com/clinical-roundup/20260925_9a/
FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma - The Cancer Letter
FDA granted approval for Lyrfigtu (lirafugratinib) as a treatment option for patients with cholangiocarcinoma with FGFR2
cancerletter.com
September 28, 2026 at 12:00 PM
ipharmaservices.bsky.social
DESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #新闻 #媒体 #肺癌
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:46 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:45 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:44 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:29 PM
ipharmaservices.bsky.social
DESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:29 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:28 PM
adnkronos.com
I risultati sono stati presentati durante il simposio presidenziale alla World Conference on Lung Cancer Iaslc 2026
Cancro polmone Egfr-mutato, studio fase 3 Adaura: "Il 79% dei pazienti vivo a 8 anni con Osimertinib"
ebx.sh
September 17, 2026 at 4:42 AM
yoshitakahoshi.bsky.social
早期EGFR変異肺がんのタグリッソ術後療法、8年生存データをAstraZenecaが発表──ADAURA試験の長期追跡結果を整理
stellanews.life/technology/1... #ADAURA #8年生存
早期EGFR変異肺がんのタグリッソ術後療法、8年生存データをAstraZenecaが発表──ADAURA試験の長期追跡結果を整理
AstraZenecaは2026年9月14日、EGFR変異陽性の早期非小細胞肺がんを対象としたADAURA第3相試験について、術後補助療法としてのタグリッソ（オシメルチニブ）の8年時点における全生存期間データを発表した。主要な結果と安全性、臨床的含意を整理する。
stellanews.life
September 16, 2026 at 10:30 PM
yoshitakahoshi.bsky.social
【タグリッソ術後、II〜IIIAの8年生存は74％対58％】
ADAURA。死亡リスクは47％低下（HR 0.53）。IB〜IIIA全体では8年生存79％対64％。
September 16, 2026 at 10:30 PM
vivereitalia.bsky.social
Cancro polmone Egfr-mutato, studio fase 3 Adaura: "Il 79% dei pazienti vivo a 8 anni con Osimertinib"
https://vivere.me/g7WT-k
Cancro polmone Egfr-mutato, studio fase 3 Adaura: "Il 79% dei pazienti vivo a 8 anni con Osimertinib"
vivere.me
September 16, 2026 at 1:34 PM
sehmagazine.bsky.social
Cancro polmone Egfr-mutato, studio fase 3 Adaura: "Il 79% dei pazienti vivo a 8 anni con Osimertinib" 
Cancro polmone Egfr-mutato, studio fase 3 Adaura: “Il 79% dei pazienti vivo a 8 anni con Osimertinib”
(Adnkronos) - Il tumore del polmone è la principale causa di morte per tumore a livello globale, rappresentando quasi un decesso su cinque (19%) per cancro. Il tumore del polmone si suddivide generalmente in tumore del polmone non a piccole cellule (Nsclc) e a piccole cellule; l’80-85% dei pazienti
www.shmag.it
September 16, 2026 at 1:32 PM
lamilano.bsky.social
Cancro polmone Egfr-mutato, studio fase 3 Adaura: “Il 79% dei pazienti vivo a 8 anni con Osimertinib”

Cancro polmone Egfr-mutato, studio fase 3 Adaura: “Il 79% dei pazienti vivo a 8 anni con Osimertinib”. Il tumore del polmone è la principale causa di morte...
Cancro polmone Egfr-mutato, studio fase 3 Adaura: “Il 79% dei pazienti vivo a 8 anni con Osimertinib”
Cancro polmone Egfr-mutato, studio fase 3 Adaura: “Il 79% dei pazienti vivo a 8 anni con Osimertinib”. Il tumore del polmone è la principale causa di morte...
lamilano.it
September 16, 2026 at 1:25 PM
cancertherapyadv.bsky.social
🆕 NEW from #WCLC26! The phase 3 ADAURA trial found:

Patients with stage II-IIIA of EGFR-mutated, early-stage #NSCLC, the 8-year OS was 74% in the osimertinib arm & 58% in the placebo arm. @IASLC

Read more data from the study here: https://bit.ly/4cMq78T
September 15, 2026 at 12:56 PM
newsen.bsky.social
Long-Term Benefits of Osimertinib in Resected EGFR-Mutated NSCLC Highlighted in ADAURA Trial Update#South_Korea#Seoul#NSCLC#Osimertinib#ADAURA
Long-Term Benefits of Osimertinib in Resected EGFR-Mutated NSCLC Highlighted in ADAURA Trial Update
An eight-year follow-up from the ADAURA trial reveals osimertinib's sustained overall survival advantage for patients with resected EGFR-mutated NSCLC, reinforcing its standard treatment status.
third-news.com
September 14, 2026 at 2:55 PM
blueresearch.bsky.social
AstraZeneca reports updated exploratory results from ADAURA trial
Reported Monday, Sep 14 - 5:29am EDT (TheFly subscription required to read more.)
thefly.com
September 14, 2026 at 9:30 AM
thecancersurvivorsclub.com
Long-term survival continues to improve for some people with EGFR-mutated lung cancer. Tagrisso has produced encouraging long-term survival results following surgery for early-stage disease.

www.astrazeneca.com/media-centre...

#LungCancer #CancerTreatment #TCSC
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
www.astrazeneca.com
September 14, 2026 at 7:51 AM
medicalxpress.com.web.brid.gy
Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
medicalxpress.com
September 14, 2026 at 3:40 AM
silkunderground.bsky.social
a bird with an aura. an adorable aura. an adaura.
#birds
an eastern wood peewee perched at the end of a stick in green woods, glowing in the sun.
May 18, 2026 at 10:14 PM
hemeoncbuddy.bsky.social
Heme/onc fellows starting July,
you already in love with thoracic oncology? ➡️ save this.

A free reference platform:
• Trials (LAURA, ADAURA, AEGEAN, KEYNOTE-189, MARIPOSA +)
• Board prep notes
• Heme/onc flashcards
• Staging flashcards (incl. lung TNM 9th ed)

🔗 HemeOncBuddy.org
HemeOncBuddy
Heme/Onc education hub for fellows. 1,500+ pivotal trial summaries, close to 2,000 board-prep flashcards, and 120+ disease-site notes — free, searchable, no login.
hemeoncbuddy.org
May 18, 2026 at 1:00 PM
sophie0899lo.bsky.social
Such a meaningful milestone. As someone who’s followed the EGFR story closely since ADAURA, FLAURA-2’s NICE approval feels both expected and hard-earned. The Blueteq note is subtle but huge—single cycle allowed, yet no path forward post-adjuvant PD? Curious how this will shift UK practice. Thoughts?
August 6, 2025 at 5:59 PM
lisasitu.bsky.social
Out today: Molecular Residual Disease Precedes Disease-Free Survival Events by Months, a #ResearchWatch summary of an impactful exploratory post hoc analysis of the ADAURA trial by Dr. Roy Herbst, Dr. Thomas John, Dr. Yi-Long Wu, and colleagues

aacrjournals.org/cdnews/news/...
Molecular Residual Disease Precedes Disease-Free Survival Events by Months
Major Finding: Molecular residual disease (MRD) preceded death or clinical recurrence in the ADAURA trial by nearly 5 months. Concept: Longitudinal MRD monitoring may stratify risk for patients with E...
aacrjournals.org
June 12, 2025 at 2:41 PM
medicine.stitches.today
Molecular residual disease analysis suggests prolonged osimertinib treatment may benefit patients with resected EGFR-mutated non-small-cell lung cancer.

by Herbst RS, John T (...) Wu YL et 20 al. in Nat Med #MedSky

📖 read the article:
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that molecular residual disease detection predicts disease recurrence with long-term adjuvant osimertinib treatment.
www.nature.com
March 26, 2025 at 4:39 PM
hhorinouchi.bsky.social
🔥 @natmedicine.bsky.social 🆙
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...
March 22, 2025 at 5:28 PM